首页> 外文期刊>Modern Pathology >Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-Cell lymphoma
【24h】

Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-Cell lymphoma

机译:声波刺猬信号蛋白和ATP结合盒G2在弥漫性大B细胞淋巴瘤中异常表达

获取原文
           

摘要

Dysregulation of the sonic hedgehog (SHH) signaling pathway has been shown in several cancer types, but has not been explored in diffuse large B-cell lymphoma. We assessed 67 cases of diffuse large B-cell lymphoma for expression of SHH (ligand), GLI1, GLI2 and GLI3 (transcriptional effectors of SHH signaling), and the ATP-binding cassette (ABC)G2 (a downstream target of SHH signaling), using immunohistochemistry. For comparison, we assessed the expression levels of these proteins in 28 cases of follicular lymphoma, 5 chronic lymphocytic leukemia/small lymphocytic lymphoma, and 5 reactive lymph nodes. In diffuse large B-cell lymphoma, SHH was expressed in 61 of 67 (91%) cases, GLI1 in 62 of 67 (93%), GLI2 in 41 of 56 (73%), and GLI3 in 22 of 56 (39%). Expression of ABCG2 was detected in 52 of 55 (95%) cases and was high in 15 (27%) cases. SHH expression positively correlated with expression levels of ABCG2 (P=0.05). Patients with diffuse large B-cell lymphoma with high ABCG2 expression showed significantly shorter overall survival (P=0.031) and failure-free survival (P=0.029) compared with patients with tumors with low or no expression of ABCG2. Diffuse large B-cell lymphomas expressed SHH, and GLI1, GLI2, and GLI3 more frequently and more intensely than cases of follicular lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma. In conclusion, our data show that SHH signaling proteins and ABCG2 are aberrantly expressed in diffuse large B-cell lymphoma and that ABCG2 expression has prognostic implications. These findings also provide evidence that dysregulation of the SHH pathway may be involved in the pathogenesis of diffuse large B-cell lymphoma.
机译:声音刺猬(SHH)信号通路的失调已在几种癌症类型中显示,但尚未在弥漫性大B细胞淋巴瘤中进行探讨。我们评估了67例弥漫性大B细胞淋巴瘤的SHH(配体),GLI1,GLI2和GLI3(SHH信号的转录效应子)和ATP结合盒(ABC)G2(SHH信号的下游靶标)的表达,使用免疫组织化学。为了进行比较,我们评估了这些蛋白在28例滤泡性淋巴瘤,5例慢性淋巴细胞性白血病/小淋巴细胞性淋巴瘤和5例反应性淋巴结中的表达水平。在弥漫性大B细胞淋巴瘤中,SHH在67例中占61(91%),GLI1在67例中占62(93 %),GLI2在56例中占41(73 %),GLI3在56例中占22 (39 %)。 55例(95%)患者中有52例检测到ABCG2的表达,而15例(27%)患者中ABCG2的表达较高。 SHH表达与ABCG2表达水平呈正相关(P = 0.05)。与ABCG2低表达或无ABCG2表达的患者相比,ABCG2高表达的弥漫性大B细胞淋巴瘤患者的总生存期(P = 0.031)和无衰竭生存期(P = 0.029)显着缩短。弥漫性大B细胞淋巴瘤比滤泡性淋巴瘤或慢性淋巴细胞性白血病/小淋巴细胞性淋巴瘤病例更频繁,更强烈地表达SHH,GLI1,GLI2和GLI3。总之,我们的数据表明SHH信号蛋白和ABCG2在弥漫性大B细胞淋巴瘤中异常表达,并且ABCG2的表达具有预后意义。这些发现也提供证据,SHH通路的失调可能与弥漫性大B细胞淋巴瘤的发病机制有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号